

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 April 2003 (03.04.2003)

PCT

(10) International Publication Number  
**WO 03/027270 A1**

(51) International Patent Classification<sup>2</sup>: C12N 5/06,  
A61K 35/39

C12N 5/06,

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/NZ02/00197

(22) International Filing Date:  
27 September 2002 (27.09.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:  
514546 28 September 2001 (28.09.2001) NZ

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): DIA-TRANZ LIMITED [NZ/NZ]; 19 Laureston Avenue, Otahuhu, 1006 Manakau City (NZ).

Published:

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): GARKAVENKO, Olga [NZ/NZ]; 3/30 Simkin Avenue, St Johns, 1005 Auckland (NZ).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agent: ENSOR, Donald, Rivers; Linsor et Associates, 111 Western Springs Road, Mt Albert, 1002 Auckland (NZ).



A1

**WO 03/027270**

(54) Title: GROWING XENOTRANSPLANT MATERIAL IN CULTURE

(57) Abstract: Over time, cultured mammalian cells aggregate into an artificial tissue with 10% homologous serum and nicotinamide. Neonatal porcine islets alone have a SGS index of 4.6. Co-culture with neonatal porcine Sertoli cells formed free-floating islet-like structures, 300-600 microns in diameter (SGS index 21). Basal secretion of insulin remains high for islets in a heavily confluent mixed cell culture. Re-seeded cultures were very responsive to glucose (SGS index 21.8). Co-culture with fibroblasts also provides a high SGS index, permitting use of the recipient's fibroblast line as support/trophic cells for an xenotransplantable graft, as for treatment of diabetes.

BEST AVAILABLE COPY

**TITLE**      **Growing xenotransplant material in culture.****FIELD**

This invention generally relates to growing biological material by cell/tissue culture methods in order to make material suitable for transplanting into a mammal in order to overcome a disease, deficiency, or defect. More particularly the invention relates to preparations of cells and cell combinations for use in xenotransplantation, and specifically the invention relates to transplants of endocrine secretory cells such as islet cells for treating diabetes present within the recipient.

**BACKGROUND**

A patient afflicted with the irreversible disease diabetes has defective islets of Langerhans and cannot produce sufficient insulin to respond appropriately to blood glucose increase. Since the discovery of insulin by Banting et al in 1922, exogenous (injected) insulin in repeated doses has comprised an effective method of control of blood glucose and has greatly extended the lives of many diabetics. Implants for use in controlling endogenous secretion defects such as diabetes are known, where ideally the implant would (a) produce sufficient insulin to avoid any need for use of injections or other means of administration of insulin, and also (b) assume a regulatory role, responding to swings in blood glucose concentration by producing a greater amount of insulin if the environment of the implant has an increased concentration of glucose. Kidney and pancreas, or pancreas alone allotransplantation is done from cadaver sources or sometimes live donors, but faces the usual problems of rejection involving immune responses. Islet transplantation after enzymic digestion of a cadaver pancreas is also known (e.g. Shapiro et al).

Xenotransplants of islet cells present a number of advantages, such as avoidance of certain diseases. For an xenotransplant, barriers of various types are used at least to confine the cells to a permanently identifiable, often subcutaneous site as well as to avoid an immune system challenge from the patient yet not detracting from the intended function. Specific pathogen free (SPF) pigs are suitable donors for xenografts of many types because of their anatomical and physiological similarities with humans and the porcine pancreas has been considered as a

potential source of islets for xenotransplantation in diabetic patients. However, the high cost of SPF herd maintenance as well as the necessity to tightly control potential zoonoses has led to efforts to propagate islets *in vitro* - a kind of organ culture. Growing of animal cells *in vitro* for xenotransplantation if it were possible would provide many advantages including cost savings, and better control of the product, including better control of infectious pathogens such as potentially zoonotic viruses.

Previous research papers have shown only limited *in vitro* growth of adult and neonatal islets of different species. Neonatal tissue has a good capacity for growth in tissue culture, although a clear disadvantage of neonatal islet tissue is functional immaturity, which results in a period of 6-8 weeks before the grafted cells are able to regulate the hyperglycemia in diabetic recipients (see for example Korsen O, Jansson L, Eizirik DL, Andersson A. "Functional and morphological differentiation of fetal porcine islet-like cells clusters after transplantation into nude mice". *Diabetologia* 1991; 34:379). It is also relatively difficult to hold differentiated cells (such as islet cells) in culture over long periods without reversion to a poorly differentiated version.

There are many other forms of disease where the possibility of inserting extra material into the body in order to overcome the problem exists. For example, replacement of functions not or no longer available from other endocrine glands, the liver, or muscles or tendons, cartilage as blocks or other shapes for reconstruction, and lumps of bone.

One problem to be solved is to raise potentially insulin-secreting cells in a culture from, for example, neonatal porcine pancreatic tissue; including the step of maintaining the cells for an extended period. Another problem to be solved is to provide an effective xenotransplant capable of making an effective amount of insulin when exposed to hyperglycaemic conditions, despite the usual presence of a physical barrier intended to limit access of members of the immune system to the foreign cells.

## OBJECT

It is an object of this invention to create an improved cell preparation for use in xenotransplants, or at least to provide the public with a useful choice.

## DEFINITIONS

**homologous serum:** a serum for cell culture, taken from the same species of animal as that from which the cells were derived.

**artificial tissue:** a mixture, made *de novo* of more than one kind of living cell in tissue/ cell culture, and after a period of time characteristically exhibiting (a) at least some physiological support of one kind of cell by another kind, and (b) at least some distinctive structural configuration including the cells of the mixture.

**connective tissue secretory cells;** a group including cells capable of secreting and supporting components of an extracellular matrix, such as chondrocytes, osteocytes, fibrocytes, including fibrocytes from tendons and fibrocytes from the dermis of the skin, and undifferentiated fibroblasts. This may include stem cells.

**endocrine secretory cells:** a group including, but not limited to: anterior pituitary cells, thyroid and parathyroid cells, pancreatic islet cells, adrenal cortical cells, ovarian and testicular cells including interstitial cells, choroid plexus cells, and the like.

Other first-type cells (as used herein) include any functional cell types including those of epithelial, connective tissue, or neural origin especially hepatocytes.

**support/trophic cells:** includes Sertoli cells, fibroblasts, some types of neuroglial cells, secretory cells including choroid plexus epithelial cells, and stem cells. Modified support/trophic cells include cells modified by alteration of their genetic composition so that they secrete a range of compounds similar to those secreted by, for example, Sertoli cells in a tissue culture environment and capable of promoting the growth and development of functional characteristics of secretory cells when grown in association.

**long-term :** a period of more than a week; typically extended to 4-6 weeks or more.

## **STATEMENT OF INVENTION**

In a first broad aspect this invention provides a method for carrying out long-term *in vitro* assembly, propagation and maturation of a functional artificial tissue comprised of more than one kind of cell taken from at least one species of mammal, wherein a selected first type of cell capable of being stimulated to secrete a product is co-cultured over an extended period together with at least one selected second type of cell capable of providing a support/trophic function for the first type, in a growth medium supplemented with an effective amount of homologous serum from the species of mammal that provided the first type of cell, so that organised functional synergistic groups of mixed cell types are developed over the extended period.

In a subsidiary aspect the invention provides a method as previously described in this section for making a functional artificial tissue wherein the artificial tissue includes a selected first type of cell and a second type of cell jointly capable of possessing a property, and is grown as a co-

culture in a growth media supplemented with an effective amount of homologous serum, so that the artificial tissue may be grafted into a recipient suffering from a deficiency of the property in order to alleviate the deficiency.

Preferably the first type of cell is selected from the group of endocrine secretory cells (as herein defined) and the product is an endocrine hormone.

Preferably the second type of cell is selected from a group including Sertoli cells and fibroblasts.

Optionally the first type of cell is not an endocrine cell.

In a related aspect, the effective amount of homologous serum is in a range of from about 5% to about 15% by volume in the growth medium.

In a second related aspect, the growth media also includes nicotinamide within a range of from about 5 mM to about 15 mM.

Preferably at least the first type of cell is collected from a neonatal mammal.

Preferably, for making a functional artificial tissue for use in alleviation of diabetes, the first type of cell is endocrine cells from the pancreatic islets of Langerhans.

More particularly the artificial tissue is grown as a co-culture in a growth media supplemented with an effective amount of homologous serum, glucose, and nicotinamide, so that the resulting artificial tissue exhibits a functional secretory response to a local concentration of glucose, so that the artificial tissue may be grafted into a recipient suffering from diabetes in order to alleviate the disease.

In a third related aspect, the second type of cell is taken by biopsy from an individual in need of a functional graft and after *in vitro* propagation and maturation together with the first type of cell for a period the resulting co-culture is returned to the diabetic recipient in the form of a functional artificial tissue.

Preferably the second-type cells are fibroblasts, obtained from a specific individual intended as a subject for a subsequent xenografting procedure in which the individual receives subsequent generations of the fibroblasts as an allograft.

Typically, functional cell combinations have been grown as a co-culture for from about 30 to about 50 days in growth media of this type.

In a second broad aspect, the invention provides a functional artificial tissue comprised of more than one kind of cell taken from at least one species of mammal, wherein the functional artificial tissue is comprised of at least partially organised synergistic accumulations of cells

comprised of a first type of cell, capable of being stimulated to secrete a product, and at least one second type of cell capable of providing a support/trophic function for the first type of cell, the functional artificial tissue being formed by co-culture *in vitro* over an extended period of time.

Preferably the first type of cell is selected from the range of endocrine secretory cells, and is capable of expressing effective amounts of at least one secretion into the growth medium when in association with the second type of cell, so that the one or more secretions may be isolated from time to time for use.

In a subsidiary aspect, the secreted product from a functional artificial tissue the secretion includes an effective amount of insulin.

In a related aspect, the functional artificial tissue is preserved for transport, storage and later use in a state of metabolic arrest.

In a further related aspect, the functional cells include cells capable of forming an extracellular matrix which may be shaped to suit a graft or transplant, including chondrocytes, osteocytes, fibrocytes from tendons, and the skin.

Preferably the effective amount of serum from the same species of mammal is at least 5% and more preferably is about 10%.

Preferably the effective amount of nicotinamide is at least 5 mM and more preferably is about 10 mM.

More preferably the invention provides an example tissue culture environment comprising Sertoli cells as a food layer for islet cells in the growth media known as RPMI 1640 media supplemented with 10% porcine serum, 10 mM nicotinamide, and 11.1 mM glucose (noting that these numbers are examples).

Preferably the Sertoli cells are from the same species of animal; more preferably they are from the same animal.

Preferably a ratio of seeded Sertoli cells to seeded islet cells is about 10,000 to 1 islet-equivalent (IEQ).

As alternatives to Sertoli cells as support/trophic cells, one may use other cells having similar characteristics; unmodified cells include certain neuroglial cells, secretory cells including choroid plexus epithelial cells,

Otherwise, modified cells include cells modified by alteration of their genetic composition so that they secrete a range of compounds similar to those secreted by Sertoli cells in a tissue culture environment.

In a second related aspect the invention provides functional cell combinations as previously described in this section, which have been grown together for at least 50 days in growth media of this type.

Alternatively the invention provides groups of islet cells which have been grown together for at least 30 days in growth media of this type.

In a third broad aspect the invention provides living material suitable for use in an xenotransplant; the material including groups of islet cells grown in an environment including (a) nicotinamide, (b) homologous (same species) serum, and (c) Sertoli cells all in a mutually effective amount.

Preferably the living material is encapsulated and a preferred encapsulation is carried out according to the Calafiore method.

Optionally the living material is provided in a metabolically slowed, or preserved state for transport or storage.

In a fourth broad aspect the invention provides a method of *in vitro* propagation and differentiation of functional islets in a medium as previously described in this section, using Sertoli cells as a matrix and a "nurse or feeder" layer.

Preferably the method includes the steps of

1. isolating Sertoli cells from a neonatal mammal
2. isolating pancreatic islet cells or progenitors thereof from a neonatal mammal,
3. forming a cultured layer of Sertoli cells on a surface, using a growth medium as herein described,
4. adding islet cells
5. and maintaining the cell combinations over a period, until the islet cells have differentiated into functional cells, and formed concentrated masses capable of secreting insulin at least partially in response to a glucose stimulus.

In a fifth broad aspect, the invention provides a method for growing functional cells or cell associations *in vivo* and in a container including a liquid medium; the medium being separated from the cells or cell associations from time to time so that the one or more desired secretions expressed by the cells may be harvested from the cells for a pharmaceutical use.

Preferably a desired secretion is insulin.

### PREFERRED EMBODIMENT

The description of the invention to be provided herein is given purely by way of example and is not to be taken in any way as limiting the scope or extent of the invention. The specific developments that have taken place during development of this invention are in relation to xenotransplantation for cases of diabetes. However it must be realised that the Examples to follow can be applied to other types of cells, such as hepatocytes, chondrocytes, and the like.

### ILLUSTRATIONS

Fig 1. Photomicrograph of a group of adjacent islets at various stages of development. A cell monolayer forms a background to a lower focal concentration of cells (normally after 5-7 days in culture), an upper focal formation of three-dimensional structures (normally at 2-3 weeks), and in the centre an islet-like structure (normally at 3-4 weeks in culture).

Fig 2: Islet cells (Liberase H isolation) cultured for 5 weeks with HSA.

Fig 3: Islet cells (Liberase H isolation) cultured for 5 weeks with 10% porcine serum (higher magnification than fig 2).

Fig 4: Islet cells (Collagenase P isolation) cultured for 5 weeks with HSA.

Fig 5: As fig 4 but with 10% porcine serum.

Fig 6: Sertoli cells cultured for 5 weeks with HSA.

Fig 7: As fig 6 but with 10% porcine serum

Fig 8: Islets with Sertoli cells 1:100 (1 islet equivalent to 100 Sertoli cells) cultured for 5 weeks with HSA.

Fig 9: As fig 8 but with 10% porcine serum.

Fig 10: Islets with Sertoli cells 1:10,000 cultured for 5 weeks with HSA

Fig 11: As fig 10 but with 10% porcine serum; resulting in large islets.

Fig 12: Islets/Sertoli cells (1:10,000) cultured for 5 weeks with porcine serum. Diameter of islets: 300  $\mu\text{m}$  and 600  $\mu\text{m}$ .

Fig 13: As Fig 12. Diameter of islet: 600  $\mu\text{m}$ .

Figs 14-17: Comparison of sizes of islets from different cultures with 10% porcine serum: Fig 14: Islet (Collagenase P isolation) 250  $\mu\text{m}$ , Fig 15: Islets/Sertoli 1:100 = 150  $\mu\text{m}$ , Fig 16: Islets/Sertoli 1:10,000 = 500  $\mu\text{m}$ . Fig 17: Islets/Sertoli cells cultured for 46 days. Size of the islet is 400  $\mu\text{m}$ .

Fig 18: DTZ staining of Islets/Sertoli 1:10,000 with HSA (some positive staining)

Figs 19 & 20: DTZ staining of Islets/Sertoli 1:10,000 with porcine serum; 85% of cells positive to stain.

Fig 21: is a bar graph to show the insulin response of free islets after 46 days of culture and the effect of the presence of Sertoli cells during growth on the response.

Fig 22: is a bar graph to show the insulin response of encapsulated islets and the effect of the presence of porcine versus human serum during culture on the response, using a SGS test.

Fig 23: is a bar graph to show the insulin response of islet cells grown together with a variety of other cell types including the fibroblast line HEF312.

In general this invention relates to improvements in the preparation of cells for transplantation. One aspect of the improvements is the provision of better growth media for the cells during preparation for transplantation. Another aspect is the provision of a second cell type to form a supporting co-culture for the islet cells, and a preferred cell type exhibiting a combination of support and trophic effects, as it shows (among other functions) within the testis, is the Sertoli cell.

## EXAMPLE 1a

This Example relates to tissue culture methods for raising and maturing cells intended for xenotransplantation.

**Porcine Islet Cell Isolation.** Pancreatic islets from 7 day old piglets were prepared following an adapted method from C. Ricordi (Pancreatic Islet cell Isolation. Austin R.G. Landes Co. 99:112, 1992). Our method includes enzymatic digestion (collagenase, liberase), culture for three days at 37 deg C in RPMI 1640 containing 2% human serum albumin, Ciproxin and 10 mmol/L nicotinamide in an atmosphere of 5% CO<sub>2</sub> and 95% air. Viability was tested with DTZ staining

and insulin release *in vitro*.

**Porcine Sertoli Cell Isolation Cell Cultures in Combination.** Testicles from the same piglets were collected in HBSS solution including antibiotics. The isolation of Sertoli cells was done following the Rajotte procedure with some modifications (Rajotte, Diabetes, Vol 46, February 1997 317-322). The testicles were cleaned, separated from the capsule, and minced into 1 mm pieces with scissors. Digestion was done using DNA-ase and collagenase in a pre-heated waterbath at 37°C. Viability was tested using Sudan III and Trypan blue.

**Cell Cultures in Combination.** A set of flasks was maintained for 50 days, using a variety of media as per the following list. The media was changed weekly hence some components may change in concentration during the week. The base is RPMI 1640 media supplemented with either 2% HSA (human serum albumin or 10% porcine serum, 10mM nicotinamide, and 11.1 mM glucose, and the following combinations and variations were tested:

1. Control Islets with 2 % HSA
2. Islets with 10% porcine serum
3. Control Sertoli cells with 2 % of HSA.
4. Sertoli with 10% porcine serum
5. Control Islets /Sertoli 1:100 with 2% HSA.
6. Islets/Sertoli 1:100 with 10% porcine serum
7. Control Islets/Sertoli 1:10.000 with 2% HSA.
8. Islets/Sertoli 1:10.000 with 10% porcine serum

Samples were taken at day 46 for static stimulation with glucose (SGS) (Figs 21-22) and viability tests with DTZ (figs 18-20) and AO/PI staining. Results are expressed through photomicrographs Figs 1-20. Summary Fig 1 is a photomicrograph of a group of islets illustrating different stages of development close to each other, A cell monolayer forms a background to a focal concentration of cells as in the lower part of the picture (normally seen after 5-7 days in culture). In the upper part of this photomicrograph there is an early stage of formation of three-dimensional structures (normally seen at 2-3 weeks), and in the centre an islet-like structure (normally seen at 3-4 weeks in culture).

Compare fig 2 (islet cells (Liberase H isolation) cultured for 5 weeks with HSA) against fig 3 showing cells of the same origin cultured for 5 weeks with 10% porcine serum (at a slightly higher magnification than fig 2). An islet exists in the example where homologous (pig) serum

is used. The human serum culture lacks evidence of growing cells.

Compare fig 4 (Islet cells (Collagenase P isolation) cultured for 5 weeks with HSA) against fig 5 - the same but with 10% porcine serum. Again, an islet is present with homologous serum while the human serum culture appears to be moribund.

Compare fig 6 of Sertoli cells cultured for 5 weeks with HSA in the absence of islet cells against fig 7 (using 10% porcine serum); it appears that the homologous serum is beneficial to Sertoli cells - preceding Figures also showed that homologous serum is beneficial to islet cells. The next set examines co-cultures.

Compare fig 8 Islets with Sertoli cells in the ratio of 1:100 (1 islet equivalent for every 100 Sertoli cells) cultured for 5 weeks using HSA, against fig 9 (using 10% porcine serum). There is some cell activity in a co-culture with HSA but islet formation is seen only within the porcine serum flask.

Using 1 islet equivalent (IEQ) for every 10,000 Sertoli cells appears to be more optimal. In fig 10 that ratio with human serum resulted in no islet formation; whereas in fig 11, 10% porcine serum results in large islets. Further examples using porcine serum at 10% are shown in Figs 12 and 13. Diameter of islets: 300  $\mu\text{m}$ , 600  $\mu\text{m}$ , and 600  $\mu\text{m}$ .

Figs 14 to 17 show various sizes of islets from differently treated cultures all raised with 10% porcine serum: Fig 14: Islet (Collagenase P isolation) 250  $\mu\text{m}$ , Fig 15: Islets/Sertoli 1:100 = 150 $\mu\text{m}$ , Fig 16: Islets/Sertoli 1:10,000 = 500  $\mu\text{m}$ . Fig 17: Islets/Sertoli cells cultured for 46 days and the size of this islet is 400  $\mu\text{m}$ .

DTZ (dithizone) staining is shown in Figs 18, 19 and 20. Fig 18 grown under HSA (Islets/Sertoli 1:10,000) showed some positive staining. Figs 19 and 20 are two examples of (the same co-culture ratio with 10% porcine serum. Here at least 85% of cells stained positively for this test of insulin secretion.

One could conclude that there appears to be a synergistic co-operation between the use of homologous serum (in this case, 10% porcine serum) and co-culturing of islet cells with at least the Sertoli cells used in this Example, because only when both components are present is there formation of well-defined rounded islet structures as shown in many of the photomicrographs. This phenomenon could be described as "organogenesis" - if one can call an islet of Langerhans an organ. It appears that diameters of about 600 microns is the upper limit of size at least for the protocols tested to date, and this may be related to oxygenation of the cells at the centre of each ball.

## EXAMPLE 1b

Insulin release tests (SGS test; Figs 21 & 22). Fig 21 is a bar graph to show the insulin response of free islets after 46 days of culture and the effect of the presence of Sertoli cells during growth on the response. Fig 22 is a bar graph to show the insulin response of encapsulated islets and the effect of the presence of porcine versus human serum during culture on the response.

All the cells used in Fig 21 were cultured for 46 days in medium supplemented with 10% porcine serum. The maximal insulin release for free islets at day 46 was 46.1 uU/100 IEQ/hr compared to 114 uU/100 IEQ/hr when islets were co-incubated with Sertoli cells. Interestingly, the maximal insulin release was significantly higher when the mixture of Sertoli/islet cells was re-seeded one week before the SGS with a maximal insulin release of 356.7 uU/100 IEQ/hr compared to 46.99 uU/100 IEQ/hr from re-seeded islets not as a co-culture. Interestingly, islet cells in co-culture with Sertoli cells were able to produce some insulin even though there were lot of apoptotic cells (see photo 18). These results confirm that Sertoli cells preserve the beta-cell function.

The same islets were then encapsulated in alginate according to methods described by Calafiore et al (see Calafiore Basta & Boselli, Transplant Proc 1997; 29: 2126-7, ("Effect of alginate/polyaminoacidic coherent microcapsules (CM) transplantation in adult pigs") and Calafiore, Basta & Falorni, Diabetes Nutr Metab 1991; 4: 45-48 ("Vascular graft of microencapsulated human pancreatic islets in non immunosuppressed diabetic recipients; preliminary results") and cultured with human or porcine serum. The insulin release results are shown in Fig 22. "Static stimulation Encapsulated Islets: Human vs Porcine serum". The average maximal insulin release after 10 days was 54.57 uU/100 IEQ/hr for the encapsulated islets maintained with porcine serum compared to 128 uU/100 IEQ/hr when cultured with human serum. However, after 36 days in culture insulin release decreased to 54 uU/100 IEQ/hr for encapsulated islets with HAS and increased to 154 uU/100 IEQ/hr for encapsulated islets with porcine serum.

In order to demonstrate the effect of serum species on functional cell numbers, see the photomicrograph Fig 18: which is of a culture using Islets/Sertoli cells in a ratio of 1:10.000 with HAS. Only some islets still show some positive DTZ staining. In comparison, DTZ staining in Figs 19 and 20 with the same ratio of cell types but with porcine serum shows that more than 85% of the cells are DTZ positive cells.

It should be noted that we did not seek an immunological barrier comprised of Sertoli cells.

**EXAMPLE 1C** DNA flow cytometry. A major concern for workers in this art is that the neonatally derived cells may undergo a potentially malignant transformation. Thus, for any long-term culture of cells-precursors the control of "normality" is very important. Flow cytometry has been used to check the ploidy of the cultured cells in this study. Table 1 represents the DNA content following different treatments.

**Table 1. DNA content in different experiment settings after 50 days in culture.**

Treatment \ Resulting ploidy	Diploid	Tetraploid	Aneuploid
Islet cells with 2% HSA ( <i>no events</i> )	0	0	0
Islet cells (Liberase H isolation) with 10% porcine serum	93.6%	4.91%	0.44%
Islet cells ( Collagenase P isolation) with 10% porcine serum	93%	5%	0.88%
Islet/Sertoli cells with 2% HSA	0.03%	0%	0%
Islet/Sertoli cells with 10% porcine serum	88.2%	9.89%	0.9%
PK15 (porcine embryo kidney cell line) as a same-species control	66.6%	24.9%	3.72%

## EXAMPLE 1d

This Example relates to another tissue co-culture method for raising and maturing islets in combination with the recipient's own fibroblasts as obtained for example from a skin punch biopsy. Fibroblasts appear to be at least an equivalent to Sertoli cells. in terms of a synergistic supporting relationship, and the resulting cell groups are suitable for xenotransplantation. The recipient's fibroblasts (allocells) are used as a feeder layer and ideally would grow over the surface of a globule of islet cells during tissue culture and form a surface layer capable of at least partial immunoisolation so that the islet-fibroblast structures can be put into the recipient for insulin production. This isolation should prolong the effective life of the xenotransplant. This idea can be extended to the usage of any other recipient cells such as endothelial cells, chondrocytes etc.

**Experimental procedures.** Porcine islets isolated according to example 1a were put in co-culture with human primary (non-transformed) fibroblasts as well as with other cell types to compare

the extent of proliferation and both amount and responsiveness of insulin release. The following cell types were used as a feeder layer:

1. Human embryonic kidney (HEK293) [ATCC CRL-1573]
2. HeLa line
3. Human fibroblasts (HEF312) [Auckland Hospital]
4. Porcine islet cells
5. Porcine Sertoli cells

Flasks with RPMI 1640 media supplemented with either 2% HSA or 10% porcine serum, 10mM Nicotinamide, and 11.1 mM glucose were maintained for 40 days:

1. Control Islets/human fibroblasts with 2 % H.S.A. (human serum albumin)
1. Islets/human fibroblasts with 10% porcine serum
2. Control islets/Sertoli cells with 2 % of H.S.A.
3. Islets/Sertoli with 10% porcine serum
4. Control Islets /HeLa with 2%H.S.A.
5. Islets/HeLa with 10%porcine serum
6. Control Islets/HEK293 with 2%H.S.A.
7. Islets/HEK293 1:10.000 with 10% porcine serum

The media was changed twice per week. After 40 days in co-culture, assessment of results was carried out. Photomicrographs were taken. Samples were also taken at day 40 for static stimulation with glucose (SGS) and DTZ staining. As shown in Fig \_\_\_\_ the best result from the standardised SGS procedure was obtained from the islet/fibroblast co-culture, with about 1350 micro-units per 100 IEQ/hour, and the output of insulin dropped subsequently. Although this Example has not included the initial step of obtaining a large number of fibroblasts from a skin biopsy (we used a fibroblast line known as HEF312), the validity of the use of fibroblasts has been demonstrated.

## VARIATIONS

This Example may also relate to tissue culture methods for raising and bringing to functional maturity various cells and functional cell groups, other than islet cells, which are intended for xenotransplantation.

Note that the concentrations of porcine serum have been simply set at 10% without any attempt so far to ascertain an optimum amount. Nevertheless this Example covers such variations, just as it covers other concentrations of nicotinamide apart from the specified 10 mM. Further, the amount of glucose in the culture media used has not yet been the subject of experiment.

Apart from Sertoli cells, known to have an immunologically privileged position, it may be possible to use as trophic and supportive cells other types of cells including genetically modified cells, and unmodified neural support (neuroglial) cells, fibroblasts, adult stem cells, and chondrocytes.

Indeed, Example 1d supports the use of fibroblasts. There may be further benefit in using mixtures of Sertoli (or other types of) cells and fibroblasts together with porcine islet cells.

It may become ethically acceptable to maintain, for an individual, a bank of "spare cells" preserved in case of later need. This might include individuals at the onset of clinical diabetes, or individuals having a known susceptibility to a disease. It may also include homograft techniques wherein human cells (that is, Sertoli and islet cells or precursors thereof) are raised together, if needed, in the presence of human serum and the resulting islet cell groups may be encapsulated and returned to the individual. Incidentally the Sertoli cells may be from a different individual because it is unlikely that Sertoli cells will be included within the masses of islet cells that are encapsulated and used in transplants.

#### COMMERCIAL BENEFITS or ADVANTAGES

Growing of animal cells *in vitro* for xenotransplantation (as compared to harvesting islets from mature animal pancreases) facilitates the procedure of encapsulated islet preparation, and would allow better control of infectious pathogens such as potentially zoonotic viruses, even retroviruses.

The invention also provides for the manufacture of cell secretions based on *in vitro* preparations, as an alternative to recombinant or synthetic manufacture. The advantage being that any glycosylation or the like of the peptide or proteins produced is provided by the mammalian cells themselves, and that any contaminating micro-organisms may be excluded from the products.

This invention provides a supply of islet cell groups suitable for encapsulation by known means and then for use in xenotransplants; the advantage of this invention being that the cell groups are larger, more active and available in greater quantities than was formerly possible.


Finally, it will be understood that the scope of this invention as described and/or illustrated within this provisional specification is not limited to the preferred embodiments described herein for illustrative purposes. Those of skill will appreciate that various modifications, additions, and substitutions are possible without departing from the scope and spirit of the invention as set forth in the following claims.

**CLAIMS:**

1. A method for carrying out long-term *in vitro* assembly, propagation and maturation of a functional artificial tissue comprised of more than one kind of cell taken from at least one species of mammal, characterised in that a selected first type of cell capable of being stimulated to secrete a product is co-cultured over an extended period together with at least one selected second type of cell capable of providing a support/trophic function for the first type, in a growth medium supplemented with an effective amount of homologous serum from the species of mammal that provided the first type of cell, so that organised functional, synergistic groups of mixed cell types are developed over the extended period.
2. A method as claimed in claim 1 for making a functional artificial tissue characterised in that the artificial tissue includes a first type of cell and a second type of cell jointly capable of possessing a functional property on being co-cultured in a growth media supplemented with an effective amount of homologous serum, so that the artificial tissue may be grafted into a recipient suffering from a deficiency of the property, to alleviate the deficiency.
3. A method as claimed in claim 1, characterised in that the first type of cell is selected from the group of endocrine secretory cells and the product is an endocrine hormone.
4. A method as claimed in claim 3, characterised in that the second type of cell is selected from a group including Sertoli cells and fibroblasts.
5. A method as claimed in claim 1, characterised in that the effective amount of homologous serum is in a range of from about 5% to about 15% by volume in the growth medium.
6. A method as claimed in claim 1, characterised in that the growth medium also includes nicotinamide within a range of from about 5 mM to about 15 mM.
7. A method as claimed in claim 1, characterised in that at least the first type of cell is collected from a neonatal mammal.
8. A method as claimed in claim 4 for making a functional artificial tissue characterised in that the first type of cell is endocrine cells from the pancreatic islets of Langerhans and that a ratio of the first type of cell to the second type of cell is optimised.


9. A method as claimed in claim 8 for making an artificial tissue characterised in that the artificial tissue is grown as a co-culture in a growth media supplemented with an effective amount of homologous serum, glucose, and nicotinamide, so that the resulting artificial tissue exhibits a functional secretory response to a local concentration of glucose, so that the artificial tissue may be grafted into a recipient suffering from diabetes in order to alleviate the disease.
10. A method as claimed in claim 9 further characterised in that the second type of cell is taken from an individual in need of a functional graft and after *in vitro* propagation and maturation together with the first type of cell for a period is returned to the diabetic recipient in the form of a functional artificial tissue.
11. A method as claimed in claim 10 further characterised in that the functional cell combinations have been grown as a co-culture for from about 30 to about 50 days in growth media of this type.
12. A functional artificial tissue comprised of more than one kind of cell taken from at least one species of mammal, characterised in that the functional artificial tissue is comprised of at least partially organised synergistic accumulations of cells comprised of a first type of cell, capable of being stimulated to secrete a product, and at least one second type of cell capable of providing a support/trophic function for the first type of cell, the functional artificial tissue being formed by co-culture *in vitro* over an extended period of time.
13. A functional artificial tissue as claimed in claim 12, characterised in that the first type of cell is selected from the range of endocrine secretory cells, and is capable of expressing effective amounts of at least one secretion into the growth medium when in association with the second type of cell, so that the one or more secretions may be isolated from time to time for use.
14. A secreted product from a functional artificial tissue as claimed in claim 13, characterised in that the secretion is insulin.
15. A functional artificial tissue as claimed in claim 12, characterised in that the functional artificial tissue is preserved in a state of metabolic arrest suitable for transport, storage and later use.

1/11




**Fig 1**

2/11




**Fig 2**




**Fig 3**

3/11




**Fig 4**




**Fig 5**

4/11




**Fig 6**




**Fig 7**

5/11




**Fig 8**




**Fig 9**

6/11




**Fig 10**




**Fig 11**

7/11




**Fig 12**




**Fig 13**


8/11




**Fig 14**



**Fig 15**




**Fig 16**




**Fig 17**


9/11



**Fig 18**




**Fig 19**




**Fig 20**

10/11

**Static Stimulation:**  
**Free islets vs Sertoli & Islets 46 days culture. Fig 21**



**Static Stimulation:**  
**Encapsulated islets: Human vs porcine serum**



11/11




Fig 23

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ02/00197

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl. <sup>7</sup> : C12N 005/06; A61K 35/39 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) <b>SEE ELECTRONIC DATABASES (BELOW)</b> Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched <b>SEE ELECTRONIC DATABASES (BELOW)</b>		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS MedLine CA Biosis: tissue culture, co-culture pancreas, islets of Langerhans, insulin, Sertoli cells, fibroblasts, pigs, swine		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/28167 A1 (RESEARCH CORPORATION TECHNOLOGIES INC) 26 October 1995	1-15
X	Rabinovitch A; Russell T; Mintz D H. Factors from fibroblasts promote pancreatic islet B cell survival in tissue culture. Diabetes. 1979. 28 (12): 1108-13.	1-9
A	Verhoeven G and Cailleau J. Influence of co-culture with Sertoli cells on steroidogenesis in immature rat Leydig cells. Mol Cell Endocrinol. 1990. 71: 239-251.	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search 21 November 2002	Date of mailing of the international search report <b>28 NOV 2002</b>	
Name and mailing address of the ISA/AU  AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer  Gillian Allen Telephone No : (02) 6283 2266	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ02/00197

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Maria-Engler SS, Mares-Guia M, Correa ML, Oliveira EM, Aita CA, Krogh K, Genzini T, Miranda MP, Ribeiro M, Vilela L, Noronha IL, Eliaschewitz FG, Sogayar MC. Microencapsulation and tissue engineering as an alternative treatment of diabetes. Braz J Med Biol Res. 2001 Jun; 34(6): 691-7. Review	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

PCT/NZ02/00197

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 95/28167	AU 22893/95, CA 2187803, EP0755258, JP 9512015T,

END OF ANNEX

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**